31.19
price up icon0.39%   0.0739
 
loading
Schlusskurs vom Vortag:
$31.12
Offen:
$30.5
24-Stunden-Volumen:
457.89K
Relative Volume:
0.19
Marktkapitalisierung:
$5.88B
Einnahmen:
$217.77M
Nettoeinkommen (Verlust:
$-438.86M
KGV:
-12.94
EPS:
-2.41
Netto-Cashflow:
$-456.33M
1W Leistung:
-6.86%
1M Leistung:
+7.43%
6M Leistung:
+29.84%
1J Leistung:
-12.37%
1-Tages-Spanne:
Value
$30.50
$31.35
1-Wochen-Bereich:
Value
$30.50
$33.94
52-Wochen-Spanne:
Value
$21.62
$41.04

Bridgebio Pharma Inc Stock (BBIO) Company Profile

Name
Firmenname
Bridgebio Pharma Inc
Name
Telefon
(650) 391-9740
Name
Adresse
3160 PORTER DR., PALO ALTO, CA
Name
Mitarbeiter
556
Name
Twitter
Name
Nächster Verdiensttermin
2024-10-31
Name
Neueste SEC-Einreichungen
Name
BBIO's Discussions on Twitter

Vergleichen Sie BBIO mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
BBIO
Bridgebio Pharma Inc
31.25 5.88B 217.77M -438.86M -456.33M -2.41
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
449.54 117.23B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
661.70 72.75B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
647.63 38.65B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
264.22 34.69B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
113.28 27.45B 3.30B -501.07M 1.03B -2.1146

Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-10-16 Eingeleitet Scotiabank Sector Outperform
2024-10-03 Eingeleitet Oppenheimer Perform
2024-09-04 Eingeleitet Piper Sandler Overweight
2024-03-21 Fortgesetzt Raymond James Outperform
2024-01-31 Eingeleitet BMO Capital Markets Market Perform
2023-12-08 Eingeleitet Wells Fargo Overweight
2023-11-07 Eingeleitet Citigroup Buy
2023-10-24 Eingeleitet Cantor Fitzgerald Overweight
2023-07-18 Herabstufung Jefferies Buy → Hold
2023-04-19 Eingeleitet Evercore ISI Outperform
2023-02-06 Eingeleitet Cowen Outperform
2021-12-27 Bestätigt Mizuho Buy
2021-12-27 Bestätigt SVB Leerink Outperform
2021-09-10 Hochstufung BofA Securities Neutral → Buy
2021-05-21 Eingeleitet UBS Buy
2021-03-22 Bestätigt Goldman Buy
2021-02-22 Fortgesetzt JP Morgan Overweight
2021-02-09 Fortgesetzt Goldman Buy
2021-01-11 Bestätigt H.C. Wainwright Buy
2020-12-10 Bestätigt H.C. Wainwright Buy
2020-06-25 Eingeleitet BofA/Merrill Neutral
2020-05-19 Eingeleitet BTIG Research Buy
2020-04-13 Eingeleitet H.C. Wainwright Buy
2020-02-19 Eingeleitet Mizuho Buy
2019-07-26 Eingeleitet Raymond James Outperform
2019-07-22 Eingeleitet BMO Capital Markets Outperform
2019-07-22 Eingeleitet Goldman Buy
2019-07-22 Eingeleitet JP Morgan Overweight
2019-07-22 Eingeleitet Jefferies Buy
2019-07-22 Eingeleitet Piper Jaffray Overweight
2019-07-22 Eingeleitet SVB Leerink Outperform
Alle ansehen

Bridgebio Pharma Inc Aktie (BBIO) Neueste Nachrichten

pulisher
08:46 AM

BridgeBio shares rise on Scotiabank price target boost By Investing.com - Investing.com South Africa

08:46 AM
pulisher
07:34 AM

BridgeBio gets EU nod for ATTR cardiomyopathy drug - pharmaphorum

07:34 AM
pulisher
06:40 AM

EC grants marketing authorisation to BridgeBio’s ATTR-CM treatment - Yahoo Finance

06:40 AM
pulisher
Feb 11, 2025

BridgeBio wins EU approval for Beyonttra for ATTR-CM - The Pharma Letter

Feb 11, 2025
pulisher
Feb 11, 2025

Merck KGaA pursuing Springworks; BridgeBio wins EU drug OK - BioPharma Dive

Feb 11, 2025
pulisher
Feb 11, 2025

BridgeBio Pharma Says Beyonttra Gets EU Marketing Approval for Transthyretin Amyloidosis - Marketscreener.com

Feb 11, 2025
pulisher
Feb 11, 2025

BridgeBio announces EC marketing authorization for BETONTTRA - TipRanks

Feb 11, 2025
pulisher
Feb 11, 2025

BEYONTTRA™ (acoramidis), the First Near Complete TTR - GlobeNewswire

Feb 11, 2025
pulisher
Feb 11, 2025

BBIO Secures Major EU Win: Revolutionary Heart Drug Shows 42% Mortality Reduction - StockTitan

Feb 11, 2025
pulisher
Feb 10, 2025

BridgeBio's Heart Disease Drug Meets Late-stage End Points - BW Healthcare World

Feb 10, 2025
pulisher
Feb 08, 2025

Why BridgeBio Pharma, Inc. (BBIO) Is Among the Best Healthcare Stocks To Buy According to Analysts - Insider Monkey

Feb 08, 2025
pulisher
Feb 08, 2025

BridgeBio Pharma (NASDAQ:BBIO) Stock Price Down 5.5% Following Insider Selling - MarketBeat

Feb 08, 2025
pulisher
Feb 07, 2025

BridgeBio: Post Attruby Approval, Shares Don't Look Such Good ValueRating Downgrade - Seeking Alpha

Feb 07, 2025
pulisher
Feb 05, 2025

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Short Interest Update - MarketBeat

Feb 05, 2025
pulisher
Feb 04, 2025

How To Trade (BBIO) - Stock Traders Daily

Feb 04, 2025
pulisher
Feb 04, 2025

BBIO (BridgeBio Pharma) Operating Cash Flow per Share : $-2.50 (TTM As of Sep. 2024) - GuruFocus.com

Feb 04, 2025
pulisher
Feb 04, 2025

Why BridgeBio Pharma Inc. (BBIO) Crashed on Monday - Insider Monkey

Feb 04, 2025
pulisher
Feb 04, 2025

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Major Shareholder Sells $106,989,998.40 in Stock - MarketBeat

Feb 04, 2025
pulisher
Feb 03, 2025

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CFO Sells $2,467,720.00 in Stock - MarketBeat

Feb 03, 2025
pulisher
Feb 03, 2025

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Neil Kumar Sells 326,932 Shares - MarketBeat

Feb 03, 2025
pulisher
Feb 01, 2025

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Sold by Moody Aldrich Partners LLC - MarketBeat

Feb 01, 2025
pulisher
Jan 31, 2025

Andreas Halvorsen Reduces Stake in BridgeBio Pharma Inc - GuruFocus.com

Jan 31, 2025
pulisher
Jan 31, 2025

BridgeBio Pharma Insider Sold Shares Worth $2,467,761, According to a Recent SEC Filing - Marketscreener.com

Jan 31, 2025
pulisher
Jan 31, 2025

Brokerages Set BridgeBio Pharma, Inc. (NASDAQ:BBIO) PT at $49.00 - MarketBeat

Jan 31, 2025
pulisher
Jan 29, 2025

Is BridgeBio Pharma, Inc. (BBIO) the Unstoppable Stock to Buy in 2025? - Insider Monkey

Jan 29, 2025
pulisher
Jan 27, 2025

BBIO (BridgeBio Pharma) Cash Flow for Dividends : $0.0 Mil (TTM As of Sep. 2024) - GuruFocus.com

Jan 27, 2025
pulisher
Jan 27, 2025

BBIO (BridgeBio Pharma) EBITDA : $-350.3 Mil (TTM As of Sep. 2024) - GuruFocus.com

Jan 27, 2025
pulisher
Jan 27, 2025

Why BridgeBio Pharma (BBIO) Is Skyrocketing Now - MSN

Jan 27, 2025
pulisher
Jan 26, 2025

BridgeBio Pharma, Inc. (BBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire

Jan 26, 2025
pulisher
Jan 25, 2025

14,302 Shares in BridgeBio Pharma, Inc. (NASDAQ:BBIO) Acquired by Atomi Financial Group Inc. - MarketBeat

Jan 25, 2025
pulisher
Jan 24, 2025

(BBIO) Trading Report - Stock Traders Daily

Jan 24, 2025
pulisher
Jan 24, 2025

Equities Analysts Set Expectations for BBIO FY2025 Earnings - MarketBeat

Jan 24, 2025
pulisher
Jan 24, 2025

Research Analysts Issue Forecasts for BBIO FY2025 Earnings - Defense World

Jan 24, 2025
pulisher
Jan 24, 2025

Leerink Partnrs Has Negative Estimate for BBIO Q4 Earnings - Defense World

Jan 24, 2025
pulisher
Jan 23, 2025

Cantor Fitzgerald Predicts BBIO FY2025 Earnings - MarketBeat

Jan 23, 2025
pulisher
Jan 23, 2025

Leerink Partnrs Analysts Reduce Earnings Estimates for BBIO - MarketBeat

Jan 23, 2025
pulisher
Jan 23, 2025

BridgeBio’s Neil Kumar on an underdog drug launch and wooing deal-hungry investors - BioPharma Dive

Jan 23, 2025
pulisher
Jan 23, 2025

Why Is Andreas Halvorsen Bullish On BridgeBio Pharma, Inc. (BBIO) Now? - Insider Monkey

Jan 23, 2025
pulisher
Jan 21, 2025

First Week of March 21st Options Trading For BridgeBio Pharma (BBIO) - Nasdaq

Jan 21, 2025
pulisher
Jan 21, 2025

Top 4 Health Care Stocks You May Want To Dump In Q1 - Benzinga

Jan 21, 2025
pulisher
Jan 20, 2025

Moss Adams Wealth Advisors LLC Acquires New Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat

Jan 20, 2025
pulisher
Jan 19, 2025

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Short Interest Up 12.7% in December - MarketBeat

Jan 19, 2025
pulisher
Jan 17, 2025

BridgeBio Pharma (NASDAQ:BBIO) Stock Price Up 6.6%Time to Buy? - MarketBeat

Jan 17, 2025
pulisher
Jan 17, 2025

Hypoparathyroidism Market Anticipated to Expand Rapidly During 2024-2034, Says DelveInsight | Bridgebio/Calcil ytix Therapeutics, Ascendis Pharma, EnteraBio, Shire - Barchart

Jan 17, 2025

Finanzdaten der Bridgebio Pharma Inc-Aktie (BBIO)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Bridgebio Pharma Inc-Aktie (BBIO) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
VIKING GLOBAL INVESTORS LP
10% Owner
Jan 31 '25
Sale
34.90
3,065,616
106,989,998
22,055,375
STEPHENSON BRIAN C
Secretary, Treasurer & CFO
Jan 28 '25
Option Exercise
17.00
68,000
1,156,000
161,758
STEPHENSON BRIAN C
Secretary, Treasurer & CFO
Jan 28 '25
Sale
36.29
68,000
2,467,761
93,758
Kumar Neil
Chief Executive Officer
Jan 28 '25
Sale
36.29
326,932
11,863,381
5,371,515
Kumar Neil
Chief Executive Officer
Jan 29 '25
Sale
36.35
273,068
9,925,269
5,098,447
$79.87
price down icon 0.10%
$32.33
price up icon 0.25%
$4.56
price up icon 2.24%
$368.99
price up icon 4.47%
biotechnology ONC
$222.79
price up icon 0.77%
$113.27
price down icon 1.03%
Kapitalisierung:     |  Volumen (24h):